Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00264433 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent
A Phase 2 study, sponsored by Adherex Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00264433 is a Phase 2 study that has completed, run by Adherex Technologies.
The verdict
NCT00264433, a Phase 2 study, has completed, sponsored by Adherex Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin. This study will examine the clinical activity of ADH-1.
Interventions
- DRUG ADH -1 (Exherin™)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00264433
The ClinicalTrials.gov registry entry for NCT00264433 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Adherex Technologies, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ADH -1 (Exherin™) is the first listed.
NCT00264433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00264433 about?
NCT00264433 is a clinical study titled "A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent". N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N...
What is the current status of trial NCT00264433?
This trial is currently completed. It is a Phase 2 study.
What interventions are being tested in trial NCT00264433?
The interventions under investigation include: ADH -1 (Exherin™) (DRUG).
Who is sponsoring clinical trial NCT00264433?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.